Evidence map›Paper›PMID 31423256›Full record

ArticleOncology letters2019

Clinicopathological characteristics and survival of primary malignant melanoma of the esophagus.

Tadayoshi Hashimoto, Tomoki Makino, Makoto Yamasaki, Koji Tanaka, Yasuhiro Miyazaki, Tsuyoshi Takahashi, Yukinori Kurokawa, Masaaki Motoori, Yutaka Kimura, Kiyokazu Nakajima and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Tadayoshi HashimotoDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Tomoki MakinoDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Makoto YamasakiDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Koji TanakaDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Yasuhiro MiyazakiDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Tsuyoshi TakahashiDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Yukinori KurokawaDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Masaaki MotooriDepartment of Surgery, Osaka General Medical Center, Osaka 558-8558, Japan.
Yutaka KimuraDepartment of Surgery, Kindai University Faculty of Medicine, Osaka 589-8511, Japan.
Kiyokazu NakajimaDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Eiichi MoriiDepartment of Pathology, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan.
Masaki MoriDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
Yuichiro DokiDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Osaka University · JPKindai University · JPKyushu University · JPOsaka City General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary malignant melanoma of the esophagus (PMME) has been reported to be a rare and highly malignant disease, and to date a standard treatment strategy has not been established due to limited evidence. The aim of the present study was to investigate the clinicopathological characteristics of this extremely rare disease. A total of 6 out of 2,093 patients with PMME treated in our institution between 1995 and 2016 were retrospectively analyzed and their clinicopathological parameters including treatment course and long-term survival were investigated. The major clinicopathological characteristics of patients were that they were >70 years of age, male sex, dysphagia at first diagnosis, and macroscopic black protruding tumors located in the lower third of the thoracic esophagus. Four of the five patients receiving pretherapeutic endoscopic biopsy were correctly diagnosed with PMME, and two patients received preoperative treatment with ineffective histopathological responses. There were two unresectable cases, one was treated with an immune-checkpoint inhibitor and the other received palliative care. Three of the four patients receiving curative surgery developed hematogenous recurrence within two years of surgery and only one patient with pT1aN0M0 achieved long-term survival. The median overall survival of all six patients was 19.6 (6.4-40.5) months. Patients with stage I disease exhibited significantly more favorable prognoses than those with stage II-IV (P=0.025) and surgically-treated patients had significantly better prognoses than those who did not receive surgery (P=0.018). In conclusion, PMME was associated with highly malignant features and tended to develop hematogenous metastases even after radical resection. Early diagnosis appears to be important to cure this refractory disease.

Indexed as

esophageal cancerimmune-checkpoint inhibitorprimary malignant melanoma of the esophagusprognostic factor

Identifiers

PMID31423256
PMCPMC6614672
OpenAlexW2950213904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.